Gazyvaro: new targeted lymphoma treatment

Obinutuzumab (Gazyvaro) is licensed for previously untreated chronic lymphocytic lymphoma (CLL) in patients who are ineligible for intensive therapy with full-dose fludarabine.

Patients should receive premedication with an analgesic, antihistamine and intravenous corticosteroid before each infusion.
Patients should receive premedication with an analgesic, antihistamine and intravenous corticosteroid before each infusion.

PHARMACOLOGY

Obinutuzumab is a monoclonal antibody that targets the CD20 antigen on the surface of B-lymphocytes, inducing direct cell death and mediating antibody-dependent cellular cytotoxicity, with less complement-dependent cytotoxicity than rituximab (another CD20-targeting antibody).1,2

CLINICAL STUDIES

The efficacy of obinutuzumab in combination with chlorambucil was compared with that of rituximab plus chlorambucil and chlorambucil monotherapy in 781 patients with previously untreated CLL who also had a co-existing condition (defined as a score of 6 or higher on the Cumulative Illness Rating Scale [CIRS] or a creatinine clearance of 30–69ml/min).2

Obinutuzumab plus chlorambucil was superior to both chlorambucil monotherapy and rituximab plus chlorambucil, with median progression-free survival of 26.7 months compared with 11.1 months and 16.3 months, respectively (p<0.001 for both comparisons).2

Infusion-related reactions and neutropenia were more common with obinutuzumab–chlorambucil than with rituximab–chlorambucil, but the risk of infection was not increased.2

References:

  1. Gazyvaro Summary of Product Characteristics, July 2014.
  2. Goede V et al. N Engl J Med 2014; 370: 1101–10.

View Gazyvaro drug record

Further information: Roche


Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more